Does pucotenlimab show improved outcomes for patients with gastroesophageal junction cancer?
Pucotenlimab (HX008) is a PD-1 inhibitor, a type of immunotherapy that helps the immune system attack cancer cells. For gastroesophageal junction cancer (GEJC), a cancer at the junction of the esophagus and stomach, pucotenlimab has shown promising results in improving treatment outcomes. A 2026 meta-analysis of six clinical trials found that pucotenlimab significantly improved response rates and survival compared to control treatments, with particular benefit when combined with certain chemotherapy regimens 46.
What the research says
The meta-analysis also identified biomarkers that may predict who benefits most from pucotenlimab. For example, patients with a PD-L1 combined positive score (CPS) of 1 or higher, or certain genetic mutations like KMT2D, were more likely to respond 46. However, these findings come from a single integrated analysis, and more research is needed to confirm them in GEJC specifically. Other PD-1 inhibitors like pembrolizumab have also shown benefits in GEJC, but pucotenlimab's specific data are still emerging 1.
What to ask your doctor
- Is pucotenlimab an option for my type of gastroesophageal junction cancer, and what is my PD-L1 status?
- Would combining pucotenlimab with oxaliplatin and capecitabine be more effective than other chemo combinations for me?
- What are the potential side effects of pucotenlimab, and how are they managed?
- Are there any biomarkers, like KMT2D mutations, that might predict my response to pucotenlimab?
- How does pucotenlimab compare to other immunotherapy options like pembrolizumab for my situation?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.